| Entry |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Fulvestrant (JAN/USP/INN); Faslodex (TN) | ||||||||||||
| Product | FULVESTRANT (Actavis Pharma), FASLODEX (AstraZeneca Pharmaceuticals LP), FULVESTRANT (Fresenius Kabi USA) | ||||||||||||
| Generic | FULVESTRANT (Accord Healthcare), FULVESTRANT (Amneal Pharmaceuticals LLC), FULVESTRANT (AstraZeneca Pharmaceuticals LP), FULVESTRANT (Athenex Pharmaceutical Division), FULVESTRANT (BluePoint Laboratories), FULVESTRANT (BluePoint Laboratories), FULVESTRANT (BluePoint Laboratories), FULVESTRANT (BluePoint Laboratories), FULVESTRANT (Cadila Healthcare Limited), FULVESTRANT (Chia Tai Tianqing Pharmaceutical Group), FULVESTRANT (Dr.Reddy's Laboratories), FULVESTRANT (GLENMARK PHARMACEUTICALS), FULVESTRANT (HBT Labs), FULVESTRANT (Hikma Pharmaceuticals USA), FULVESTRANT (Meitheal Pharmaceuticals), FULVESTRANT (Mylan Institutional LLC), FULVESTRANT (NorthStar Rx LLC), FULVESTRANT (Northstar Rx), FULVESTRANT (Sagent Pharmaceuticals), FULVESTRANT (Sandoz), FULVESTRANT (Sandoz), FULVESTRANT (Xiromed), FULVESTRANT (Zydus Pharmaceuticals (USA)) | ||||||||||||
| Formula | C32H47F5O3S | ||||||||||||
| Exact mass | 606.3166 | ||||||||||||
| Mol weight | 606.7708 | ||||||||||||
| Structure |  | ||||||||||||
| Class | Antineoplastic DG01585 Estrogen receptor antagonist Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||||||||
| Remark |
| ||||||||||||
| Efficacy | Antineoplastic, Estrogen receptor agonist/antagonist | ||||||||||||
| Disease | Breast cancer, postmenopausal (HR positive) [DS:H00031] Breast cancer, postmenopausal (HR positive, HER2 negative) [DS:H00031] | ||||||||||||
| Target | NR3A (ESR) [HSA:2099 2100] [KO:K08550 K08551] | ||||||||||||
| Pathway |
| ||||||||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576] | ||||||||||||
| Interaction | |||||||||||||
| Structure map |
| ||||||||||||
| Other map |
| ||||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L02 ENDOCRINE THERAPY L02B HORMONE ANTAGONISTS AND RELATED AGENTS L02BA Anti-estrogens L02BA03 Fulvestrant D01161 Fulvestrant (JAN/USP/INN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Antiestrogens/Modifiers Fulvestrant D01161 Fulvestrant (JAN/USP/INN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D01161 Fulvestrant (JAN/USP/INN) Drug groups [BR:br08330] Antineoplastic DG01585 Estrogen receptor antagonist D01161 Fulvestrant Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D01161 Fulvestrant Drug classes [BR:br08332] Antineoplastic DG01585 Estrogen receptor antagonist D01161 Fulvestrant Target-based classification of drugs [BR:br08310] Nuclear receptors Estrogen like receptors Estrogen receptor NR3A (ESR) D01161 Fulvestrant (JAN/USP/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D01161 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D01161 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D01161 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D01161 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D01161 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D01161 | ||||||||||||
| Other DBs |
| ||||||||||||
| KCF data | ATOM 41 1 C8x C 7.4203 -16.5528 2 C8y C 7.4203 -17.9330 3 C8x C 8.6185 -18.6231 4 C8x C 8.6185 -15.8628 5 C8y C 9.8096 -16.5528 6 C8y C 9.8037 -17.9330 7 C1x C 10.9960 -18.6281 8 C1y C 12.1942 -17.9432 9 C1y C 11.0077 -15.8679 10 C1y C 12.1942 -16.5658 11 C1x C 12.2169 -13.8129 12 C1x C 11.0191 -14.4913 13 C1z C 13.4035 -14.5109 14 C1y C 13.3866 -15.8831 15 C1x C 15.7638 -15.9121 16 C1x C 15.7803 -14.5396 17 C1y C 14.6003 -13.8392 18 O1a O 14.7331 -12.4541 19 O1a O 6.2253 -18.6237 20 C1b C 13.3801 -18.6301 21 C1b C 14.5721 -17.9469 22 C1b C 15.7641 -18.6370 23 C1b C 16.9561 -17.9539 24 C1b C 18.1480 -18.6440 25 C1b C 19.3400 -17.9609 26 C1b C 20.5319 -18.6510 27 C1b C 21.7239 -17.9678 28 C1b C 22.9159 -18.6579 29 S4a S 24.1078 -17.9748 30 C1b C 25.2998 -18.6649 31 C1b C 26.4917 -17.9819 32 C1b C 27.6837 -18.6720 33 C1d C 28.8756 -17.9887 34 O3c O 24.1108 -16.5946 35 X F 29.9914 -17.2156 36 X F 27.8928 -17.0058 37 C1a C 13.3941 -13.1303 38 C1d C 29.8649 -18.9778 39 X F 30.8541 -19.9671 40 X F 31.0764 -18.2784 41 X F 28.6534 -19.6773 BOND 44 1 4 1 1 2 2 19 1 3 1 2 2 4 8 20 1 #Down 5 9 10 1 6 20 21 1 7 10 14 1 8 21 22 1 9 13 11 1 10 22 23 1 11 11 12 1 12 23 24 1 13 12 9 1 14 24 25 1 15 2 3 1 16 25 26 1 17 3 6 2 18 26 27 1 19 5 6 1 20 27 28 1 21 6 7 1 22 28 29 1 23 7 8 1 24 29 30 1 25 13 14 1 26 30 31 1 27 15 16 1 28 31 32 1 29 16 17 1 30 32 33 1 31 17 13 1 32 29 34 2 33 14 15 1 34 8 10 1 35 17 18 1 #Up 36 9 5 1 37 33 35 1 38 5 4 2 39 33 36 1 40 13 37 1 #Up 41 33 38 1 42 38 39 1 43 38 40 1 44 38 41 1 |